STOCK TITAN
  1. Home
  2. News
  3. QRON

QRONS INC - $QRON STOCK NEWS

Welcome to our dedicated page for QRONS news (Ticker: $QRON), a resource for investors and traders seeking the latest updates and insights on QRONS stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect QRONS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of QRONS's position in the market.

News
Qrons Announces the Addition of Professor Shiri Navon-Venezia to its Scientific Advisory Board to Beef up its Team, as Part of its New Sepsis Research Program
Rhea-AI Summary
Qrons Inc. (OTCQB:QRON) has announced the addition of Professor Shiri Navon-Venezia to its Scientific Advisory Board. Professor Venezia, a renowned expert in antibiotic resistance and bacterial pathogens, will play a crucial role in shaping the company's research program to develop and commercialize Tellurium-based compounds for treating antibiotic-resistant bacterial infections, including Sepsis. With antimicrobial resistance being a global public health threat, causing over 1.27 million deaths worldwide and 2.8 million infections in the U.S. annually, Professor Venezia's expertise is highly relevant to addressing this urgent issue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Qrons Announces Launch of its New Website in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
Rhea-AI Summary
Qrons Inc. launches updated website highlighting their efforts in combating infectious diseases and sepsis, with a focus on antibiotic resistant bacteria. Antimicrobial resistance is a global health threat, causing 1.27 million deaths worldwide in 2019. The US healthcare system spends about $38 billion annually on sepsis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Qrons Announces the Filing of a Provisional Patent Application in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Qrons Announces the Signing of a License Agreement Term Sheet as Part of New Research Program to Experiment and Commercialize the Therapeutic Effect of Certain Tellurium Based Compounds on Antibiotic Resistance Bacterial Infections, Sepsis and Traumatic Brain Injuries
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.12%
Tags
none
-
News
Qrons files U.S. National Phase of its Patent Application in Furtherance of its QS200 Product Candidate for Therapeutic Polypseudorotaxane Hydrogels
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Qrons Announces a New Pre-Clinical Research Program to Test the Efficacy of Tellurium Based Compounds, in Combination with its QS200(TM) Product Candidate or Independently, in Treating Diffused Axonal Injuries and Antibiotic Resistant Bacteria and Sepsis
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
Qrons Announces Filing Of Provisional Patent Application In Furtherance Of Its QS200 Product Candidate
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
101.85%
Tags
none
-
News
Qrons Announces Effectiveness of Its Post-Effective Amendment to Its Registration Statement
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Qrons Announces U.S. Patent Office Grants Dartmouth College 3D Printing Patent Forming Basis of License Agreement with Qrons
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.56%
Tags
none
News
Qrons Announces Launch of its New Website Reflecting Expanded Neuronal Diseases Goals
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock QRON logo
QRONS INC

OTC:QRON

QRON Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

QRON Stock Data

2.52M
3.51M
74.47%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
Long Island City

About QRON

qrons inc., a preclinical stage biotechnology company, engages in developing stem cell synthetic hydrogel-based solutions to combat neuronal injuries, primarily focusing on traumatic brain injuries. its products candidates include qs100, an injury specific, 3d printable, implantable modified mesenchymal stem cells (mscs)-synthetic hydrogel to treat penetrating brain injuries; and qs200, an injectable mscs-synthetic hydrogel for the treatment of diffused injuries. qrons inc. has a license and research funding agreement with ariel university r&d co., ltd. for the development and commercialization of products for neuronal tissue regeneration and repair. the company was formerly known as biolabmart inc. and changed its name to qrons inc. in august 2017. qrons inc. was founded in 2016 and is based in new york, new york.